"Focused on Solid Evidence-Based R&D"...Hanmi Pharmaceutical to Present Most Research Among Korean Firms at AACR
Eight New Drug Research Results to Be Presented at AACR 2026 in the United States on April 17
Hanmi Pharmaceutical is expanding the foundation for new drug development outcomes based on solid evidence-based R&D.
Hanmi Pharmaceutical, the core operating company of Hanmi Science, announced on April 6 that it will participate in the American Association for Cancer Research (AACR 2026), which will be held in San Diego, United States from April 17 to 22 (local time). The company will present nine preclinical research results, the highest number among Korean pharmaceutical and biotech companies, at the event.
Introduction to Major Research Poster Abstracts Presented by Hanmi Pharmaceutical at AACR 2026. Hanmi Pharmaceutical
View original imageAt this year’s AACR, Hanmi Pharmaceutical will present poster research results for a total of eight new drug candidates, including: the dual EZH1/2 inhibitor (HM97662); the selective HER2 inhibitor (HM100714); the SOS1-KRAS interaction inhibitor (HM101207); a selective EP300 degrader; an STING mRNA anticancer drug; two p53-mRNA anticancer drugs; as well as the 4-1BB x PD-L1 bispecific antibody (BH3120) and the B7H3 x PD-L1 bispecific antibody-drug conjugate (ADC) (BH4601), both of which are being primarily developed by Beijing Hanmi Pharmaceutical.
A large number of researchers from Hanmi Pharmaceutical’s R&D Center will participate to introduce innovative projects, which is expected to open opportunities for constructive collaboration with leading global pharmaceutical companies.
Expansion of Precision Targeted Cancer Therapies Aimed at Key Oncogenic Mutations
Hanmi Pharmaceutical will present research results demonstrating the synergistic effect of combining the dual EZH1/2 inhibitor (HM97662) with a DNA damaging agent in a SMARCA4-deficient malignant lung cancer model. HM97662 is being developed as a next-generation targeted anticancer therapy that simultaneously inhibits both EZH1 and EZH2 proteins—a "dual inhibition mechanism"—and is expected to offer superior anticancer efficacy and overcome resistance compared to existing EZH2-selective inhibitors.
Additionally, Hanmi Pharmaceutical will unveil research results using artificial intelligence (AI)-based advanced analytical technology to identify optimal indications for its orally administered targeted anticancer therapy, the selective HER2 inhibitor (HM100714), which is under development for cancers with HER2 mutations. HER2 mutations are found in various cancers, including breast and lung cancer, and are known to cause cancer cell growth and metastasis. In particular, these HER2 mutations are associated with brain metastasis and leptomeningeal metastasis, acting as major factors that worsen patient prognosis and decrease survival rates.
Exterior view of Hanmi Pharmaceutical Research Center in Hwaseong-si, Gyeonggi-do
View original imageHanmi Pharmaceutical will also present research showing that the SOS1-KRAS interaction inhibitor (HM101207) regulates gene expression involved in hypoxia survival mechanisms, thereby overcoming resistance in KRAS-dependent cancers. HM101207 is a novel inhibitor (SOS1-KRAS multi inhibitor) that blocks the interaction between SOS1 and KRAS—key components in the signal transduction process responsible for activating KRAS, a well-known oncogenic mutation. It is being highlighted as a promising candidate for global anticancer combination strategies.
The selective EP300 degrader, first unveiled by Hanmi Pharmaceutical in October of last year, is being developed as an oral targeted therapy utilizing Hanmi’s new modality, the "targeted protein degradation (TPD)" platform technology. At this year’s conference, Hanmi Pharmaceutical will present research results on the discovery of an optimized selective EP300 degrader with excellent anticancer efficacy and no side effects, achieved by using advanced technologies such as molecular dynamics simulation, bioinformatics frameworks, AI, and machine learning.
Accelerating Cancer Innovation with Next-Generation Modality mRNA Platform
Hanmi Pharmaceutical will also present research achievements on immune-oncology therapies based on the next-generation "mRNA platform" modality.
The STING (Stimulator of IFN Genes) mRNA anticancer drug is a therapy that directly expresses activated STING protein, thereby inducing a potent anticancer immune response. At this conference, Hanmi will introduce research results that demonstrate not only the immune activation mechanism but also a "dual mechanism" that induces direct tumor cell death, confirming its effective anticancer efficacy.
Another mRNA platform-based drug, the p53 mRNA anticancer therapy, is designed to induce apoptosis (programmed cell death) of cancer cells by restoring normal expression of the p53 protein—a representative tumor suppressor gene—inside the cell. At this conference, Hanmi will reveal research results showing that an analog with enhanced cancer cell apoptosis mechanism compared to natural p53 has been developed, confirming its superior anticancer efficacy and demonstrating a mechanism that can overcome resistance to chemotherapy.
Furthermore, Hanmi Pharmaceutical will present research from its p53 mRNA anticancer drug program that introduces a transcriptome-based analysis approach to predict responsiveness to p53 restoration therapy in advance and systematically select cancer types with high therapeutic potential.
Beijing Hanmi R&D Center, First Disclosure of Bispecific Antibody-Drug Conjugate Projects
The R&D Center of Beijing Hanmi Pharmaceutical, Hanmi Group’s local subsidiary in China, will present new research results on the immune-oncology therapy BH3120, which is based on its bispecific antibody platform technology "Pentambody." Currently, global phase 1 clinical trials to evaluate the safety and tolerability of BH3120 are underway in Korea and the United States. In parallel with these clinical studies, the Beijing Hanmi R&D Center is conducting a variety of preclinical studies to further elucidate the in vivo mechanism of BH3120.
Through various preclinical studies, BH3120 has demonstrated not only outstanding anticancer efficacy but also a clear "decoupling" of immune activation between the tumor microenvironment (TME) and normal tissue, proving the potential for effective and safe anticancer drug development. At this conference, Hanmi will present research results on the immune mechanism of action showing that the combination of the next-generation CD3 T cell engager and BH3120—both attracting attention as cutting-edge anticancer technologies—synergistically amplifies the anticancer effect through complementary mechanisms.
The Beijing Hanmi R&D Center will also disclose, for the first time, the mechanism of action and pharmacological activity of a new anticancer project, BH4601. BH4601 is a next-generation anticancer project based on a bispecific antibody-drug conjugate (ADC) that simultaneously targets B7H3 and PD-L1. It is expected to offer a differentiated mechanism and the potential to overcome the limitations of existing ADC drugs.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
Choi Inyoung, Head of the R&D Center, stated, "The core focus of Hanmi Pharmaceutical’s new drug development is our oncology pipeline, which is expanding its innovation into various modality fields such as targeted protein degradation (TPD), messenger RNA (mRNA), cell and gene therapy (CGT), antibody-drug conjugates (ADC), and single-domain antibodies (sdAb). Based on global-level technological capabilities and state-of-the-art R&D infrastructure, we are integrating new technologies such as artificial intelligence (AI), bioinformatics (BI), and omics into all areas of research to lead the next-generation paradigm of new drug development."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.